Peter Joyce

Peter Joyce is the CEO and co-founder of Grey Wolf Therapeutics. Peter has over 10 years of experience in the pharmaceutical industry, having worked as a senior research scientist, postdoctoral research fellow, and regulatory advisor.

Joyce began their career as a senior research scientist at Vertex Pharmaceuticals, where they worked for four years developing in vivo and in vitro models of ALS. Peter then moved to the Medical Research Council, Mammalian Genetics Unit, where they spent three years fostering collaborations across Europe and the US, presenting data at international conferences, and chairing a conference session. While at the Medical Research Council, Joyce successfully published multiple first and co-author research and review publications.

In 2008, Joyce left the Medical Research Council to join Wyeth Pharmaceuticals as a regulatory advisor. After one year at Wyeth Pharmaceuticals, Joyce co-founded Molecule 2 Medicine, a pharmaceutical company specializing in the development of drugs for rare diseases. In 2012, Joyce co-founded Grey Wolf Therapeutics, a pharmaceutical company focused on developing immuno-oncology therapeutics.

Peter Joyce was educated at the University of Bristol, where they obtained a first class honours degree in biochemistry, followed by a PhD in biochemistry and genetics.

Some direct reports include Peter Littlewood - Director of DMPK, Martin Quibell - Director of Medicinal Chemistry, and Kirsty McCarthy - Head of Operations.